Back to Research Home
JNJJohnson & Johnson
Health Care · Pharmaceuticals · Mega
$263.81−1.42%
As of 23 Oct 2026Mkt cap $663B
Stage 13
WATCH
Fundamentals
44.8/75
Technical
6.3/15
Independent
51.2/90
GCAE viewbusiness is credible but technical recovery is not yet actionable
Price
- 1M
- −2.5%
- 3M
- −0.8%
- 6M
- +16.0%
- 1Y
- +36.7%
Financials & valuation
Cached filing evidence · as of 2026-10-21
Valuation
- P/E
- 40.0xHist median 21.8x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 31.1x
- FCF yield
- 3.2%
Quality
- ROIC
- 33.6%
- Operating margin
- 42.6%
- FCF margin
- 20.9%
- Current ratio
- 1.0x
Growth
- Revenue growth
- +6.0%Latest FY YoY
- Revenue CAGR
- +4.6%
- EPS CAGR
- +9.0%
- FCF CAGR
- −0.1%
Capital
- Share-count trend
- −2.6%3Y annualised
- Net debt
- $29.6B1.2x OCF
Annual trend
- CAGR 2021–2025
- +4.6%
- Latest · 2025
- $94B
- YoY
- +6.0%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
business is credible but technical recovery is not yet actionable
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2027-01-26
More details & evidence
Production decision
- Stage 13
- WATCH
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-21
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded